Marker Therapeutics, Inc. (NASDAQ:MRKR) Director Purchases $35,472.00 in Stock

Marker Therapeutics, Inc. (NASDAQ:MRKR) Director Steve Elms purchased 11,085 shares of the company’s stock in a transaction that occurred on Monday, December 23rd. The stock was bought at an average cost of $3.20 per share, for a total transaction of $35,472.00. Following the purchase, the director now directly owns 325,370 shares in the company, valued at $1,041,184. This represents a 3.53 % increase in their position. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link.

Marker Therapeutics Trading Up 0.9 %

NASDAQ:MRKR traded up $0.03 during mid-day trading on Thursday, reaching $3.41. The stock had a trading volume of 46,092 shares, compared to its average volume of 31,342. Marker Therapeutics, Inc. has a fifty-two week low of $2.44 and a fifty-two week high of $6.16. The business’s 50 day moving average is $3.71 and its 200 day moving average is $3.83.

Institutional Inflows and Outflows

A hedge fund recently raised its stake in Marker Therapeutics stock. Wedbush Securities Inc. increased its position in shares of Marker Therapeutics, Inc. (NASDAQ:MRKR) by 52.7% during the second quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 69,500 shares of the company’s stock after buying an additional 24,000 shares during the quarter. Wedbush Securities Inc. owned 0.78% of Marker Therapeutics worth $377,000 at the end of the most recent quarter. Institutional investors and hedge funds own 22.39% of the company’s stock.

Analysts Set New Price Targets

Separately, LADENBURG THALM/SH SH increased their price target on shares of Marker Therapeutics from $11.00 to $19.00 and gave the stock a “buy” rating in a research report on Monday, October 21st.

Marker Therapeutics Company Profile

Marker Therapeutics, Inc, a clinical-stage immuno-oncology company, engages in the development and commercialization of novel T cell-based immunotherapies for the treatment of hematological malignancies and solid tumor indications. Its multi tumor associated antigen-specific T cell technology is based on the manufacture of non-engineered tumor-specific T cells that recognize multiple tumor-associated antigens.